{"id":32801,"date":"2025-04-30T22:20:11","date_gmt":"2025-04-30T14:20:11","guid":{"rendered":"https:\/\/flcube.com\/?p=32801"},"modified":"2025-04-30T22:20:12","modified_gmt":"2025-04-30T14:20:12","slug":"innovent-biologics-initiates-first-in-human-dosing-of-ibi3020-in-phase-i-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32801","title":{"rendered":"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial"},"content":{"rendered":"\n

China-based Innovent Biologics, Inc. (HKG: 1801<\/a>) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted dual-payload antibody-drug conjugate (ADC), in a Phase I clinical trial for advanced solid tumors. Developed through Innovent’s proprietary DuetTx dual-payload ADC platform, IBI3020 is the first global dual-payload ADC in its class to enter clinical development.<\/p>\n\n\n\n

Clinical Trial Design<\/strong>
The open-label, global multi-center Phase I study is designed to assess the safety, tolerability, and preliminary efficacy of IBI3020 in advanced solid tumors. The trial will also determine the recommended Phase II dose (RP2D). The study is expected to be carried out in both China and the U.S., with recent IND approval in the latter.<\/p>\n\n\n\n

Preclinical Data<\/strong>
Preclinical data demonstrated potent antitumor activity across multiple xenograft models. The ADC exhibited a significant bystander effect, enhancing tumor microenvironment penetration. Additionally, IBI3020 showed a favorable safety profile with controllable toxicity thresholds.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted…<\/p>\n","protected":false},"author":1,"featured_media":32802,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,62,910,198],"class_list":["post-32801","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-hkg-1801","tag-innovent-biologics"],"yoast_head":"\nInnovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted dual-payload antibody-drug conjugate (ADC), in a Phase I clinical trial for advanced solid tumors. Developed through Innovent's proprietary DuetTx dual-payload ADC platform, IBI3020 is the first global dual-payload ADC in its class to enter clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32801\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial\" \/>\n<meta property=\"og:description\" content=\"China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted dual-payload antibody-drug conjugate (ADC), in a Phase I clinical trial for advanced solid tumors. Developed through Innovent's proprietary DuetTx dual-payload ADC platform, IBI3020 is the first global dual-payload ADC in its class to enter clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32801\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-30T14:20:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-30T14:20:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3018.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32801#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32801\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial\",\"datePublished\":\"2025-04-30T14:20:11+00:00\",\"dateModified\":\"2025-04-30T14:20:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32801\"},\"wordCount\":161,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32801#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3018.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1801\",\"Innovent Biologics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32801#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32801\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32801\",\"name\":\"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32801#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32801#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3018.webp\",\"datePublished\":\"2025-04-30T14:20:11+00:00\",\"dateModified\":\"2025-04-30T14:20:12+00:00\",\"description\":\"China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted dual-payload antibody-drug conjugate (ADC), in a Phase I clinical trial for advanced solid tumors. Developed through Innovent's proprietary DuetTx dual-payload ADC platform, IBI3020 is the first global dual-payload ADC in its class to enter clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32801#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32801\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32801#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3018.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3018.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32801#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial - Insight, China's Pharmaceutical Industry","description":"China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted dual-payload antibody-drug conjugate (ADC), in a Phase I clinical trial for advanced solid tumors. Developed through Innovent's proprietary DuetTx dual-payload ADC platform, IBI3020 is the first global dual-payload ADC in its class to enter clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32801","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial","og_description":"China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted dual-payload antibody-drug conjugate (ADC), in a Phase I clinical trial for advanced solid tumors. Developed through Innovent's proprietary DuetTx dual-payload ADC platform, IBI3020 is the first global dual-payload ADC in its class to enter clinical development.","og_url":"https:\/\/flcube.com\/?p=32801","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-30T14:20:11+00:00","article_modified_time":"2025-04-30T14:20:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3018.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32801#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32801"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial","datePublished":"2025-04-30T14:20:11+00:00","dateModified":"2025-04-30T14:20:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32801"},"wordCount":161,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32801#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3018.webp","keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","HKG: 1801","Innovent Biologics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32801#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32801","url":"https:\/\/flcube.com\/?p=32801","name":"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32801#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32801#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3018.webp","datePublished":"2025-04-30T14:20:11+00:00","dateModified":"2025-04-30T14:20:12+00:00","description":"China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted dual-payload antibody-drug conjugate (ADC), in a Phase I clinical trial for advanced solid tumors. Developed through Innovent's proprietary DuetTx dual-payload ADC platform, IBI3020 is the first global dual-payload ADC in its class to enter clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32801#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32801"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32801#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3018.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3018.webp","width":1080,"height":608,"caption":"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32801#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3018.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32801"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32801\/revisions"}],"predecessor-version":[{"id":32803,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32801\/revisions\/32803"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32802"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}